NL8601355A - Nieuwe samenstelling. - Google Patents

Nieuwe samenstelling. Download PDF

Info

Publication number
NL8601355A
NL8601355A NL8601355A NL8601355A NL8601355A NL 8601355 A NL8601355 A NL 8601355A NL 8601355 A NL8601355 A NL 8601355A NL 8601355 A NL8601355 A NL 8601355A NL 8601355 A NL8601355 A NL 8601355A
Authority
NL
Netherlands
Prior art keywords
aqueous solution
pharmaceutical composition
concentration
lyophilized pharmaceutical
solution
Prior art date
Application number
NL8601355A
Other languages
English (en)
Dutch (nl)
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB858513358A external-priority patent/GB8513358D0/en
Priority claimed from GB858521705A external-priority patent/GB8521705D0/en
Application filed by Wellcome Found filed Critical Wellcome Found
Publication of NL8601355A publication Critical patent/NL8601355A/nl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NL8601355A 1985-05-28 1986-05-27 Nieuwe samenstelling. NL8601355A (nl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB858513358A GB8513358D0 (en) 1985-05-28 1985-05-28 Formulation
GB8513358 1985-05-28
GB8521705 1985-08-31
GB858521705A GB8521705D0 (en) 1985-08-31 1985-08-31 Formulation

Publications (1)

Publication Number Publication Date
NL8601355A true NL8601355A (nl) 1986-12-16

Family

ID=26289290

Family Applications (1)

Application Number Title Priority Date Filing Date
NL8601355A NL8601355A (nl) 1985-05-28 1986-05-27 Nieuwe samenstelling.

Country Status (22)

Country Link
US (2) US4929444A (fr)
JP (1) JPH0759517B2 (fr)
AU (1) AU567236B2 (fr)
BE (1) BE904830A (fr)
CA (1) CA1300008C (fr)
CH (1) CH665356A5 (fr)
DE (1) DE3617752A1 (fr)
DK (1) DK163173C (fr)
ES (2) ES8800601A1 (fr)
FI (1) FI85335C (fr)
FR (1) FR2583984B1 (fr)
GB (1) GB2176702B (fr)
GR (1) GR861366B (fr)
HU (1) HU195733B (fr)
IL (1) IL78938A (fr)
IT (1) IT1191926B (fr)
LU (1) LU86444A1 (fr)
NL (1) NL8601355A (fr)
NO (1) NO171345C (fr)
NZ (1) NZ216307A (fr)
PT (1) PT82646B (fr)
SE (1) SE462016B (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE904831A (fr) * 1985-05-28 1986-11-27 Wellcome Found Composition d'activateur tissulaire du plasminogene.
ZW14486A1 (en) * 1985-07-29 1986-10-22 Smithkline Beckman Corp Pharmaceutical dosage unit
US5034225A (en) * 1985-12-17 1991-07-23 Genentech Inc. Stabilized human tissue plasminogen activator compositions
US4777043A (en) * 1985-12-17 1988-10-11 Genentech, Inc. Stabilized human tissue plasminogen activator compositions
DK237187A (da) * 1986-05-12 1987-11-13 Wellcome Found Farmaceutisk anvendelse af t-pa
US4976959A (en) * 1986-05-12 1990-12-11 Burroughs Wellcome Co. T-PA and SOD in limiting tissue damage
GB8619098D0 (en) * 1986-08-05 1986-09-17 Wellcome Found Combination
US5270198A (en) * 1988-05-20 1993-12-14 Genentech, Inc. DNA molecules encoding variants of tissue plasminogen activators, vectors, and host cells
US5342616A (en) * 1988-06-20 1994-08-30 The Wellcome Foundation Limited Method of administering tissue plasminogen activator
US5714145A (en) * 1988-09-02 1998-02-03 Genentech, Inc. Tissue plasminogen activator having zymogenic or fibrin specific properties
US5262170A (en) * 1988-09-02 1993-11-16 Genentech, Inc. Tissue plasminogen activator having zymogenic or fibrin specific properties and substituted at amino acid positions 296-299, DNA molecules encoding them, vectors, and host cells
DE3835350A1 (de) * 1988-10-17 1990-04-19 Boehringer Mannheim Gmbh Aktivierung von gentechnologisch hergestellten, in prokaryonten exprimierten antikoerpern
US4980165A (en) * 1989-01-27 1990-12-25 Genetics Institute, Inc. Pharmaceutical formulations of plasminogen activator proteins
DE3942142A1 (de) * 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh Stabilisierung von glykosyliertem t-pa
WO1992011866A1 (fr) * 1991-01-14 1992-07-23 Duke University SEQUENCE DE LAMININE UTILES COMME ACTIVATEUR DE tPA
DK0643772T3 (da) * 1992-06-03 1998-02-02 Genentech Inc Glycosyleringsvarianter af vævsplasminogenaktivator med forbedrede terapeutiske egenskaber
US6346510B1 (en) 1995-10-23 2002-02-12 The Children's Medical Center Corporation Therapeutic antiangiogenic endostatin compositions
JP3840262B2 (ja) * 1995-10-23 2006-11-01 ザ チルドレンズ メディカル センター コーポレイション 治療用の抗血管新生組成物および方法
ATE262537T1 (de) * 1995-12-13 2004-04-15 Childrens Medical Center Proliferationsinhibitor von endothellzellen und dessen verwendung
US6139838A (en) * 1996-09-06 2000-10-31 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Tissue plasminogen activator medicinal composition
US20030077682A1 (en) * 2001-09-07 2003-04-24 Hung Paul Porwen Human tissue urokinase type plasminogen activator formulation
US20040091465A1 (en) * 2002-06-26 2004-05-13 Zachary Yim Therapeutic antiangiogenic compositions and methods
US7670810B2 (en) * 2003-06-20 2010-03-02 Illumina, Inc. Methods and compositions for whole genome amplification and genotyping
US7491263B2 (en) * 2004-04-05 2009-02-17 Technology Innovation, Llc Storage assembly
MX2007013196A (es) * 2005-04-20 2008-01-18 Hutchinson Fred Cancer Res Metodos, composiciones y articulos de fabricacion para mejorar la supervivencia de celulas, tejidos, organos y organismos.

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3998947A (en) * 1973-11-30 1976-12-21 Pierre Fabre S.A. Process for obtaining a plasminogen activator
FR2252842B1 (fr) * 1973-12-03 1977-11-04 Fabre Sa Pierre
DE3015699C2 (de) * 1979-04-26 1982-07-15 Asahi Kasei Kogyo K.K., Osaka Herstellung eines Plasminogen-Aktivators
US4766075A (en) * 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
JPS5951220A (ja) * 1982-08-02 1984-03-24 Asahi Chem Ind Co Ltd 新規なプラスミノ−ゲン・アクチベ−タ−およびその製法ならびにこれを含有する薬剤
NL191755C (nl) * 1982-10-29 1996-07-02 Mitsui Toatsu Chemicals Plasminogeenactivator en trombolytisch middel.
AU554862B2 (en) * 1982-12-14 1986-09-04 Implico B.V. Plasminogen activator isolated by affinity chromatography
NZ206699A (en) * 1982-12-30 1989-08-29 Bio Response Inc Process for the production of serum independent cell lines
JPS59196824A (ja) * 1983-04-21 1984-11-08 Kowa Co 吸着防止剤
DE3584902D1 (de) * 1984-02-29 1992-01-30 Asahi Chemical Ind Waessrige loesung eines darin in erhoehter konzentration aufgeloesten gewebe-plasminogen-aktivators und herstellungsverfahren.
DE3439980A1 (de) * 1984-11-02 1986-05-07 Behringwerke Ag, 3550 Marburg Verfahren zur reinigung sowie pasteurisierung von urokinase
EP0201153A3 (fr) * 1985-02-09 1987-10-07 Beecham Group Plc Enzyme modifié et son procédé de préparation
GB8513358D0 (en) * 1985-05-28 1985-07-03 Wellcome Found Formulation
ZW14486A1 (en) * 1985-07-29 1986-10-22 Smithkline Beckman Corp Pharmaceutical dosage unit
JPH0672105B2 (ja) * 1985-10-02 1994-09-14 持田製薬株式会社 血栓溶解剤及びその製法

Also Published As

Publication number Publication date
US4929444A (en) 1990-05-29
IT1191926B (it) 1988-03-31
ES8802439A1 (es) 1988-06-01
NO171345B (no) 1992-11-23
AU5796486A (en) 1986-12-04
IL78938A (en) 1993-02-21
DE3617752C2 (fr) 1988-06-30
ES555353A0 (es) 1987-11-16
PT82646A (en) 1986-06-01
HU195733B (en) 1988-07-28
SE8602405D0 (sv) 1986-05-27
FR2583984B1 (fr) 1989-06-02
NZ216307A (en) 1989-10-27
ES8800601A1 (es) 1987-11-16
CH665356A5 (de) 1988-05-13
GR861366B (en) 1986-09-29
HUT41638A (en) 1987-05-28
FI85335B (fi) 1991-12-31
DK163173C (da) 1992-06-22
LU86444A1 (fr) 1986-12-05
BE904830A (fr) 1986-11-27
IL78938A0 (en) 1986-09-30
PT82646B (pt) 1989-01-30
AU567236B2 (en) 1987-11-12
NO862096L (no) 1986-12-01
CA1300008C (fr) 1992-05-05
FI862227A (fi) 1986-11-29
IT8648065A0 (it) 1986-05-27
GB2176702A (en) 1987-01-07
FR2583984A1 (fr) 1987-01-02
FI85335C (fi) 1992-04-10
JPH06183995A (ja) 1994-07-05
GB8612780D0 (en) 1986-07-02
DE3617752A1 (de) 1986-12-04
DK246786A (da) 1986-11-29
US4968617A (en) 1990-11-06
FI862227A0 (fi) 1986-05-27
NO171345C (no) 1993-03-03
DK246786D0 (da) 1986-05-27
DK163173B (da) 1992-02-03
ES557374A0 (es) 1988-06-01
JPH0759517B2 (ja) 1995-06-28
GB2176702B (en) 1989-07-05
SE8602405L (sv) 1986-11-29
SE462016B (sv) 1990-04-30

Similar Documents

Publication Publication Date Title
US4968617A (en) Solid hydrochloride salt of t-PA
US5112609A (en) Acidic formulations of t-PA
KR100450856B1 (ko) 활성 단백질 ｃ 제제
JP3537440B2 (ja) 可溶性トロンボモジュリンを長期保存安定化させる方法
JP3927248B2 (ja) Ｈｇｆ凍結乾燥製剤
AU2009240026B2 (en) Dry transglutaminase composition
JP3822383B2 (ja) 可溶性トロンボモジュリン含有組成物
CA2475738A1 (fr) Formulations de proteines c activees
US5342616A (en) Method of administering tissue plasminogen activator
JP2916947B2 (ja) Ｃｐｂ―ｉの安定化方法及び製剤組成物
JPH0369332B2 (fr)
CA1338551C (fr) Medicament a base de tpa pour troubles thrombotiques

Legal Events

Date Code Title Description
A1B A search report has been drawn up
BC A request for examination has been filed
BV The patent application has lapsed